# Candel Therapeutics, Inc. (CADL): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Candel Therapeutics, Inc. (CADL) is 21/100, ranked against 24,000+ stocks in 35 markets (Quality 25, Value 25, Momentum 54, each scored against its sector).

- StockRank: 21/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 25, Value 25, Momentum 54: each a 0-100 percentile within Healthcare.
- Position: #20,862 overall, #1,880 in Healthcare.
- Listing: United States, NGM; Healthcare / Biotechnology.
- Last close: 7.79 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors sold USD 3.6M.

Source: https://moatmap.ai/stock/CADL
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker